In the high-stakes world of oncology, time is the most precious commodity. For patients recovering from cancer treatment, the period following surgery or therapy is often defined by a "wait-and-see" approach, characterized by the lingering, silent anxiety that microscopic remnants of the disease may still be circulating within the body. On October 26, 2026, a significant milestone in clinical diagnostics was reached as Abbott launched the next-generation Oncodetect test—a molecular residual disease (MRD) assay designed to transform how clinicians monitor for cancer recurrence.
Powered by the groundbreaking MAESTRO technology developed at the Broad Institute of MIT and Harvard, this new diagnostic tool represents a leap forward in sensitivity and precision. By detecting trace amounts of cancer DNA in the bloodstream long before they would be visible on conventional imaging scans, Oncodetect offers a critical window for early intervention, potentially changing the trajectory of patient outcomes.
The Scientific Core: MAESTRO and the Power of Whole-Genome Sequencing
At the heart of the Oncodetect test is MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides), an innovation spearheaded by Viktor Adalsteinsson, senior director of the Gerstner Center for Cancer Diagnostics at the Broad Institute.
Bridging the Sensitivity Gap
Traditional liquid biopsies have long struggled with the "needle in a haystack" problem. Blood contains a vast amount of healthy, cell-free DNA, making the detection of rare, tumor-derived DNA—often shed at incredibly low concentrations—a formidable technical challenge.
The first-generation iterations of MRD tests were limited, often tracking a narrow panel of up to 200 known cancer mutations. The new Oncodetect test, utilizing the MAESTRO platform, fundamentally shifts this paradigm. By looking across the entire genome to track up to 5,000 patient-specific mutations, the test achieves an unprecedented level of resolution. Under high-input conditions, it can detect circulating tumor DNA (ctDNA) levels below one part per million. This level of sensitivity is not merely a technical achievement; it is a clinical necessity for identifying molecular residual disease—the residual cancer cells that remain post-treatment and serve as a leading indicator of future recurrence.
A Decade of Innovation: From MIT Labs to Clinical Reality
The path from a graduate student’s vision to a commercially available diagnostic test is rarely linear. For Adalsteinsson, the journey began over a decade ago at MIT, within the lab of Chris Love. There, he worked on pioneering methods for the comprehensive sequencing of single circulating tumor cells.
A Chronology of Discovery
- 2015: Adalsteinsson earns his PhD in chemical engineering and establishes his own lab at the Broad Institute. His focus shifts toward in-depth sequencing of circulating tumor DNA and understanding how metastatic cancers evolve to evade therapy.
- 2017–2022: The team at the Gerstner Center for Cancer Diagnostics analyzes thousands of liquid biopsy samples. Through this rigorous data collection, they identify the critical need for higher sensitivity without compromising specificity, leading to the birth of the MAESTRO method.
- 2023: The Broad Institute establishes a formal research collaboration with Exact Sciences (which was later acquired by Abbott in early 2026). This partnership serves as the vehicle for translating bench-side innovation into a robust, scalable clinical product.
- October 2026: Abbott officially launches the next-generation Oncodetect test, making it available for clinical use, marking the culmination of years of collaborative research between the Broad, Dana-Farber Cancer Institute, and industry partners.
Strategic Partnerships: Turning Science into Patient Care
The transition from a research tool to a clinical standard requires more than just scientific ingenuity; it requires industrial-scale expertise. The partnership between the Broad Institute and Abbott illustrates the modern model of translational medicine.
Why Collaboration Matters
According to Todd Golub, Director of the Broad Institute, the success of MAESTRO was rooted in the "collaborative ecosystem" of the Broad. "Viktor had scientific ideas to address this problem, and the collaborative nature of the Broad ecosystem with local hospitals and beyond helped bring it all together," Golub noted.
When the technology proved its potential, the Broad’s Office of Strategic Alliances and Partnering recognized that the most effective way to reach patients was through an established diagnostic leader. By licensing the technology to Exact Sciences—and subsequently transitioning that partnership to Abbott—the researchers ensured that the test met the stringent quality and regulatory standards required for clinical diagnostics.
"The promise of innovation is ultimately measured by what it can mean for patients," said Jorge Garces, divisional vice president of R&D at Abbott. "Working with the Broad, we were able to take an extraordinary scientific innovation in MAESTRO and translate it into a test designed to give physicians more information about what may remain during and after cancer treatment."
Implications for Clinical Practice and Patient Outcomes
The availability of the Oncodetect test signals a shift toward a more proactive, "precision-guided" approach to oncology.
Early Detection, Earlier Intervention
Currently, many patients must wait for follow-up imaging (such as CT or PET scans) to determine if a cancer has returned. By the time a tumor is visible on a scan, it has often grown to a point where it is significantly harder to treat.
Oncodetect changes this timeline. By identifying ctDNA in the blood—a biological signal of recurrence—physicians can potentially detect relapse months or even years before structural changes appear on an imaging screen. This early detection provides a critical window to adjust treatment regimens, initiate secondary therapies, or enroll patients in clinical trials, potentially maximizing the chances of long-term survival.
The Future of Diagnostics: Beyond MAESTRO
While the launch of Oncodetect is a major victory, the team at the Gerstner Center is not resting on their laurels. Their work continues to push the boundaries of what is possible in liquid biopsy.
The Next Wave of Innovations
Adalsteinsson and his colleagues are already looking toward the next set of challenges in cancer detection. Current research focuses on:
- Priming Agents: These are novel diagnostic drugs designed to slow the clearance of tumor DNA from the bloodstream. By "priming" the patient’s system, researchers hope to collect more tumor DNA during a standard blood draw, further enhancing the sensitivity of future tests. A company co-founded by Adalsteinsson and Golub is currently preparing these agents for human trials.
- CODEC and Methyl CODEC: These new sequencing methods represent the next evolution in accuracy, allowing for the detection of rare genetic mutations with significantly higher precision than current industry standards.
Elizabeth Gerstner, chair of the Gerstner Family Foundation, emphasizes the importance of this ongoing commitment. "We believe in their ability not only to advance groundbreaking science, but to translate discoveries into better care for patients. The launch of Oncodetect demonstrates the power of that commitment."
Conclusion: A Validation of the Broad Model
The success of the Oncodetect launch serves as a poignant validation of the Broad Institute’s foundational philosophy: that deep, genomics-driven research should be fundamentally oriented toward benefiting patients.
"When we started the Broad, the idea from the very beginning was that our genomics research would benefit patients," said Todd Golub. "It’s easy to say that, but it’s a long and arduous road. When it actually happens, it’s very satisfying and a great validation of the multidisciplinary, collaborative nature of this place."
For patients, the arrival of this test offers something that was previously in short supply: time. By converting molecular data into actionable clinical insights, the collaboration between the Broad and Abbott has moved the needle on one of medicine’s most pressing challenges, turning the abstract potential of genomic research into a tangible, life-saving reality. As the medical community adopts this technology, the hope is that cancer care will become increasingly defined not by reactive treatment, but by precise, early, and informed intervention.
About the Author
